Is XGN or FLGT more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media prefer XGN or FLGT?

In the previous week, Exagen and Exagen both had 4 articles in the media. Fulgent Genetics' average media sentiment score of 1.68 beat Exagen's score of 0.94 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, XGN or SBC?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $71.12M 2.55 -$19.95M -$0.81 N/A SBC Medical Group $175.17M 2.68 $50.99M $0.47 9.70

Is XGN or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% SBC Medical Group 27.99% 18.47% 13.10%

Does the media refer more to SRTA or XGN?

In the previous week, Exagen had 2 more articles in the media than Strata Critical Medical. MarketBeat recorded 4 mentions for Exagen and 2 mentions for Strata Critical Medical. Exagen's average media sentiment score of 0.94 beat Strata Critical Medical's score of 0.93 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Strata Critical Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XGN or TACO?

Exagen currently has a consensus price target of $9.63, suggesting a potential upside of 28.57%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Exagen is more favorable than Berto Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, XGN or TACO?

Berto Acquisition has lower revenue, but higher earnings than Exagen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $71.12M 2.55 -$19.95M -$0.81 N/A Berto Acquisition N/A N/A N/A N/A N/A

Does the media refer more to XGN or TACO?

In the previous week, Berto Acquisition had 1 more articles in the media than Exagen. MarketBeat recorded 5 mentions for Berto Acquisition and 4 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat Berto Acquisition's score of 0.64 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Berto Acquisition 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, VMD or XGN?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viemed Healthcare $301.61M 1.10 $14.93M $0.36 24.19 Exagen $71.12M 2.55 -$19.95M -$0.81 N/A

Is VMD or XGN more profitable?

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Viemed Healthcare 4.81% 10.16% 7.22% Exagen -26.61% -104.46% -28.93%

Exagen (XGN) Competitors

$7.49 +0.14 (+1.85%)

As of 03:26 PM Eastern

Compare

XGN vs. FLGT, SBC, SRTA, TACO, and VMD

Should you buy Exagen stock or one of its competitors? Exagen's main competitors and comparable companies include Fulgent Genetics (FLGT), SBC Medical Group (SBC), Strata Critical Medical (SRTA), Berto Acquisition (TACO), and Viemed Healthcare (VMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Exagen compare to Fulgent Genetics?

Exagen (NASDAQ:XGN) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Fulgent Genetics has a net margin of -26.05% compared to Exagen's net margin of -26.61%. Fulgent Genetics' return on equity of -4.93% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Exagen has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

75.3% of Exagen shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exagen has higher earnings, but lower revenue than Fulgent Genetics. Exagen is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$71.12M	2.55	-$19.95M	-$0.81	N/A
Fulgent Genetics	$322.67M	1.80	-$60.51M	-$2.82	N/A

Exagen presently has a consensus price target of $9.63, indicating a potential upside of 28.57%. Fulgent Genetics has a consensus price target of $27.50, indicating a potential upside of 30.36%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Exagen and Exagen both had 4 articles in the media. Fulgent Genetics' average media sentiment score of 1.68 beat Exagen's score of 0.94 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Exagen and Fulgent Genetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

Exagen (NASDAQ:XGN) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Exagen had 3 more articles in the media than SBC Medical Group. MarketBeat recorded 4 mentions for Exagen and 1 mentions for SBC Medical Group. Exagen's average media sentiment score of 0.94 beat SBC Medical Group's score of 0.93 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
SBC Medical Group	Positive

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$71.12M	2.55	-$19.95M	-$0.81	N/A
SBC Medical Group	$175.17M	2.68	$50.99M	$0.47	9.70

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -26.61%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
SBC Medical Group	27.99%	18.47%	13.10%

Exagen presently has a consensus price target of $9.63, suggesting a potential upside of 28.57%. SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 86.40%. Given SBC Medical Group's higher possible upside, analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Exagen has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

75.3% of Exagen shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 81.7% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

SBC Medical Group beats Exagen on 10 of the 17 factors compared between the two stocks.

How does Exagen compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Strata Critical Medical has higher revenue and earnings than Exagen. Strata Critical Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$255.98M	1.80	$41.35M	-$0.04	N/A
Exagen	$71.12M	2.55	-$19.95M	-$0.81	N/A

47.4% of Strata Critical Medical shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 15.5% of Strata Critical Medical shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Strata Critical Medical has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Exagen has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Strata Critical Medical presently has a consensus target price of $8.00, suggesting a potential upside of 53.70%. Exagen has a consensus target price of $9.63, suggesting a potential upside of 28.57%. Given Strata Critical Medical's higher possible upside, equities research analysts clearly believe Strata Critical Medical is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Strata Critical Medical has a net margin of 15.71% compared to Exagen's net margin of -26.61%. Strata Critical Medical's return on equity of -2.97% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
Exagen	-26.61%	-104.46%	-28.93%

In the previous week, Exagen had 2 more articles in the media than Strata Critical Medical. MarketBeat recorded 4 mentions for Exagen and 2 mentions for Strata Critical Medical. Exagen's average media sentiment score of 0.94 beat Strata Critical Medical's score of 0.93 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Strata Critical Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Strata Critical Medical beats Exagen on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to Berto Acquisition?

Exagen (NASDAQ:XGN) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Berto Acquisition has a net margin of 0.00% compared to Exagen's net margin of -26.61%. Berto Acquisition's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Berto Acquisition	N/A	N/A	N/A

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Exagen currently has a consensus price target of $9.63, suggesting a potential upside of 28.57%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts clearly believe Exagen is more favorable than Berto Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Berto Acquisition had 1 more articles in the media than Exagen. MarketBeat recorded 5 mentions for Berto Acquisition and 4 mentions for Exagen. Exagen's average media sentiment score of 0.94 beat Berto Acquisition's score of 0.64 indicating that Exagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Berto Acquisition	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Berto Acquisition has lower revenue, but higher earnings than Exagen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$71.12M	2.55	-$19.95M	-$0.81	N/A
Berto Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Exagen beats Berto Acquisition on 9 of the 13 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Viemed Healthcare has a net margin of 4.81% compared to Exagen's net margin of -26.61%. Viemed Healthcare's return on equity of 10.16% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	4.81%	10.16%	7.22%
Exagen	-26.61%	-104.46%	-28.93%

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Viemed Healthcare has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Exagen has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market.

In the previous week, Exagen had 3 more articles in the media than Viemed Healthcare. MarketBeat recorded 4 mentions for Exagen and 1 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 1.87 beat Exagen's score of 0.94 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Viemed Healthcare	Very Positive
Exagen	Positive

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$301.61M	1.10	$14.93M	$0.36	24.19
Exagen	$71.12M	2.55	-$19.95M	-$0.81	N/A

Viemed Healthcare presently has a consensus target price of $14.00, suggesting a potential upside of 60.73%. Exagen has a consensus target price of $9.63, suggesting a potential upside of 28.57%. Given Viemed Healthcare's higher probable upside, research analysts clearly believe Viemed Healthcare is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Viemed Healthcare beats Exagen on 10 of the 17 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$182.05M	$9.91B	$7.17B	$14.35B
Dividend Yield	N/A	2.61%	2.57%	11.71%
P/E Ratio	-9.28	33.87	273.42	25.33
Price / Sales	2.55	5.68	674.50	98.17
Price / Cash	N/A	24.78	28.42	34.96
Price / Book	9.72	5.37	10.40	6.21
Net Income	-$19.95M	$313.45M	$3.49B	$358.18M
7 Day Performance	2.55%	0.54%	-2.06%	-1.50%
1 Month Performance	12.40%	-0.79%	-0.29%	-3.52%
1 Year Performance	-19.59%	16.26%	19.04%	5.93%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	4.1568 of 5 stars	$7.49 +1.9%	$9.63 +28.6%	-24.5%	$182.05M	$71.12M	N/A	220	Positive News
FLGT Fulgent Genetics	3.8491 of 5 stars	$20.21 +0.5%	$27.50 +36.0%	-5.6%	$554.88M	$322.67M	N/A	1,315	Positive News
SBC SBC Medical Group	4.025 of 5 stars	$4.48 +1.7%	$8.50 +89.9%	+1.3%	$459.23M	$173.61M	9.50	N/A
SRTA Strata Critical Medical	1.973 of 5 stars	$5.19 +1.2%	$8.00 +54.1%	N/A	$458.72M	$197.14M	N/A	130
TACO Berto Acquisition	N/A	$10.49 +0.0%	N/A	+2.3%	$342.02M	N/A	N/A	7,892	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. FLGT, SBC, SRTA, TACO, and VMD

How does Exagen compare to Fulgent Genetics?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to Strata Critical Medical?

Summary

How does Exagen compare to Berto Acquisition?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. FLGT, SBC, SRTA, TACO, and VMD

How does Exagen compare to Fulgent Genetics?

Is XGN or FLGT more profitable?

Which has more volatility & risk, XGN or FLGT?

Do institutionals and insiders believe in XGN or FLGT?

Which has preferable valuation & earnings, XGN or FLGT?

Do analysts recommend XGN or FLGT?

Does the media prefer XGN or FLGT?

Summary

How does Exagen compare to SBC Medical Group?

Does the media refer more to XGN or SBC?

Which has preferable earnings & valuation, XGN or SBC?

Is XGN or SBC more profitable?

Do analysts recommend XGN or SBC?

Which has more volatility and risk, XGN or SBC?

Do insiders & institutionals have more ownership in XGN or SBC?

Summary

How does Exagen compare to Strata Critical Medical?

Which has preferable earnings and valuation, SRTA or XGN?

Do institutionals & insiders hold more shares of SRTA or XGN?

Which has more risk and volatility, SRTA or XGN?

Do analysts prefer SRTA or XGN?

Is SRTA or XGN more profitable?

Does the media refer more to SRTA or XGN?

Summary

How does Exagen compare to Berto Acquisition?

Is XGN or TACO more profitable?

Do insiders and institutionals hold more shares of XGN or TACO?

Do analysts prefer XGN or TACO?

Does the media refer more to XGN or TACO?

Which has more volatility and risk, XGN or TACO?

Which has preferable valuation and earnings, XGN or TACO?

Summary

How does Exagen compare to Viemed Healthcare?

Is VMD or XGN more profitable?

Do insiders & institutionals have more ownership in VMD or XGN?

Which has more volatility and risk, VMD or XGN?

Does the media favor VMD or XGN?

Which has higher valuation & earnings, VMD or XGN?

Do analysts recommend VMD or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools